Kristi McIntyre

6.5k citations

39 papers · 1.9k indexed · 1 hit paper · h-index 16

Oncology top 2%
Cancer Research top 2%
Pulmonary and Respiratory Medicine top 5%
Molecular Biology
Genetics top 10%

Co-authors: Joyce O’Shaughnessy Svetislava J. Vukelja John Pippen Frankie A. Holmes Joanne L. Blum Lina Asmar Stephen E. Jones Kristi A. Boehm
Topics: Cancer Treatment and Pharmacology (21 papers)HER2/EGFR in Cancer Research (19 papers)Breast Cancer Treatment Studies (18 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaCancer Research
Partner nations: United States Spain United Kingdom

In The Last Decade

Kristi McIntyre

38 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

2018 516 citations Sibylle Loibl, Joyce O’Shaughnessy et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Kristi McIntyre

Since Specialization

Citations

This map shows the geographic impact of Kristi McIntyre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristi McIntyre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristi McIntyre more than expected).

Fields of papers citing papers by Kristi McIntyre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristi McIntyre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristi McIntyre. The network helps show where Kristi McIntyre may publish in the future.

Co-authorship network of co-authors of Kristi McIntyre

This figure shows the co-authorship network connecting the top 25 collaborators of Kristi McIntyre. A scholar is included among the top collaborators of Kristi McIntyre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristi McIntyre. Kristi McIntyre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer 2024 ·European Journal of Cancer ·Sara M. Tolaney,Valentina Guarneri,Jae Hong Seo,Josefina Cruz,Miguel Henriques Abreu,Masato Takahashi,Carlos H. Barrios,Kristi McIntyre,Ran Wei,María del Mar Muñoz,Belén San Antonio,Astra M. Liepa,Miguel Martín,Stephen Johnston,Pirkko‐Liisa Kellokumpu‐Lehtinen,Nadia Harbeck	10
2	93MO Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC) 2023 ·ESMO Open ·Nadia Harbeck,Valentina Guarneri,Jae Hong Seo,Josefina Cruz Jurado,(unknown),(unknown),Carlos H. Barrios,Kristi McIntyre,Ran Wei,Belén San Antonio,Astra M. Liepa,M. Martín Jiménez,SR Johnston,Sara M. Tolaney	1
3	A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer 2021 ·SHILAP Revista de lepidopterología ·Peter Muscarella,Tanios Bekaii‐Saab,Kristi McIntyre,Alexander S. Rosemurgy,Sharona Ross,Donald Richards,William E. Fisher,Patrick J. Flynn,(unknown),Claire Coeshott,Heinrich Röder,Joanna Roder,Frank E. Harrell,Allen Lee Cohn,Timothy C. Rodell,David Apelian,(unknown)	17
4	Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer 2019 ·BMC Cancer ·Lee S. Schwartzberg,Kristi McIntyre,Sharon Wilks,Shannon Puhalla,Joyce O’Shaughnessy,(unknown),Yaohua He,Linda T. Vahdat	5
5	Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study 2019 ·The Oncologist ·Vicky Jones,Kristi McIntyre,Devchand Paul,Sharon Wilks,(unknown),Scot Sedlacek,Anton Melnyk,(unknown),Yunfei Wang,(unknown),Joyce O’Shaughnessy	15
6	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialbreakdown → 2018 ·The Lancet Oncology ·Sibylle Loibl,Joyce O’Shaughnessy,Michael Untch,William M. Sikov,Hope S. Rugo,Mark D. McKee,Jens Huober,Mehra Golshan,Gϋnter von Minckwitz,David Maag,Danielle Sullivan,Norman Wolmark,Kristi McIntyre,José Ponce,Otto Metzger,Priya Rastogi,W. Fraser Symmans,Xuan Liu,Charles E. Geyer	516
7	Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer 2018 ·Cancer Medicine ·Frankie A. Holmes,Beth A. Hellerstedt,John Pippen,Svetislava J. Vukelja,(unknown),Darren M. Kocs,Joanne L. Blum,Kristi McIntyre,Minal Barve,(unknown),Cynthia R. Osborne,Yunfei Wang,Lina Asmar,Joyce O’Shaughnessy	2
8	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial 2017 ·Journal of Clinical Oncology ·Ian Smith,Denise A. Yardley,Howard A. Burris,Richard de Boer,Dino Amadori,Kristi McIntyre,Bent Ejlertsen,Michael Gnant,W. Jonat,Kathleen I. Pritchard,Mitch Dowsett,Lowell L. Hart,(unknown),(unknown),(unknown),Barbara D. Wamil,Joyce O’Shaughnessy	68
9	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine 2015 ·Clinical Cancer Research ·Joyce O’Shaughnessy,Hartmut Koeppen,Yuanyuan Xiao,Mark R. Lackner,Devchand Paul,Christopher Stokoe,John Pippen,(unknown),Frankie A. Holmes,Svetislava J. Vukelja,(unknown),Scot Sedlacek,Ragene Rivera,Robert J. Brooks,Kristi McIntyre,Carrie Brownstein,Silke Hoersch,Joanne L. Blum,Stephen E. Jones	37
10	Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies 2015 ·SpringerPlus ·Joyce O’Shaughnessy,Kristi McIntyre,Lee S. Schwartzberg,Sharon Wilks,Shannon Puhalla,(unknown),James Song,Linda T. Vahdat	14
11	Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer 2015 ·Clinical Breast Cancer ·John W. Smith,Svetislava J. Vukelja,Anthony Hoffman,Vicky Jones,Kristi McIntyre,(unknown),James Song,Joyce O’Shaughnessy	13
12	Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer 2014 ·Breast Cancer Research and Treatment ·Kristi McIntyre,Joyce O’Shaughnessy,Lee S. Schwartzberg,Stefan Glück,(unknown),James Song,David L. Cox,Linda T. Vahdat	48
13	Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling 2013 ·BMC Research Notes ·Frankie A. Holmes,Virginia Espina,Lance A. Liotta,Yasir M. Nagarwala,Michael Danso,Kristi McIntyre,Cynthia R. Osborne,T Anderson,(unknown),Joanne L. Blum,John Pippen,Allison Florance,Janine Mahoney,Joyce O’Shaughnessy	50
14	CD30 expression in nonlymphomatous malignancies. 2012 ·Journal of Clinical Oncology ·Jeff P. Sharman,Jerome H. Goldschmidt,John M. Burke,Beth A. Hellerstedt,Kristi McIntyre,Christopher A. Yasenchak,Thomas E. Boyd,Robert L. Ruxer,Dipti Patel‐Donnelly,Fadi S. Braiteh,Andres Forero‐Torres,Michael A. Savin,Tina Albertson	10
15	P5-13-03: Correlation of Clinical and Molecular Findings with Pathologic Response to Preoperative Lapatinib and Trastuzumab, Separately or in Combination, Prior to Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer. 2011 ·Cancer Research ·(unknown),Virginia Espina,(unknown),Jae C. Chang,(unknown),Michael Danso,Kristi McIntyre,(unknown),(unknown),(unknown),(unknown),J. O’Shaughnessy	4
16	Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses. 2011 ·Journal of Clinical Oncology ·John Pippen,Devchand Paul,Christopher Stokoe,Joanne L. Blum,(unknown),(unknown),Deborah Lindquist,Scot Sedlacek,Ragene Rivera,Robert J. Brooks,S. Vukelja,Kristi McIntyre,(unknown),J. O’Shaughnessy	9
17	Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer 2010 ·Breast Cancer Research and Treatment ·Nicholas J. Robert,Paul Conkling,Mark Allen O’Rourke,(unknown),Kristi McIntyre,Feng Zhan,Lina Asmar,Yanping Wang,Oluwatoyin Shonukan,Joyce O’Shaughnessy	16
18	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 2009 ·Journal of Clinical Oncology ·Stephen E. Jones,Frankie A. Holmes,Joyce O’Shaughnessy,Joanne L. Blum,Svetislava J. Vukelja,Kristi McIntyre,John Pippen,(unknown),Robert Kirby,John F. Sandbach,William Hyman,Donald Richards,Robert Mennel,Kristi A. Boehm,Wally Meyer,Lina Asmar,Daniel Mackey,Stefan Riedel,Hyman B. Muss,Michael A. Savin	400
19	Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer 2009 ·Breast Cancer Research and Treatment ·John W. Smith,Kristi McIntyre,(unknown),Carlos A. Encarnacion,Karen L. Tedesco,Yunfei Wang,Lina Asmar,Joyce O’Shaughnessy	14
20	Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer 2008 ·Clinical Breast Cancer ·David Loesch,Lina Asmar,Kristi McIntyre,(unknown),(unknown),Devchand Paul,Svetislava J. Vukelja,Mauro Orlando,(unknown),Feng Zhan,Kristi A. Boehm,Joyce O’Shaughnessy	24

About Kristi McIntyre

Kristi McIntyre is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 39 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (21 papers), HER2/EGFR in Cancer Research (19 papers) and Breast Cancer Treatment Studies (18 papers). The work is most often cited by research in Cancer Research (959 citations), Oncology (1.6k citations) and Pulmonary and Respiratory Medicine (405 citations). Kristi McIntyre has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Joyce O’Shaughnessy, Svetislava J. Vukelja, John Pippen, Frankie A. Holmes, Joanne L. Blum, Lina Asmar, Stephen E. Jones, Kristi A. Boehm, Donald Richards and Michael A. Savin. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact